Septerna (NASDAQ:SEPN) Stock Price Down 8.5% – What’s Next?

Septerna, Inc. (NASDAQ:SEPN) shares were down 8.5% during trading on Friday . The company traded as low as $18.91 and last traded at $19.08. Approximately 45,386 shares traded hands during trading, a decline of 71% from the average daily volume of 158,137 shares. The stock had previously closed at $20.85.

Wall Street Analysts Forecast Growth

SEPN has been the subject of a number of research analyst reports. TD Cowen initiated coverage on shares of Septerna in a research note on Tuesday, November 19th. They issued a “buy” rating for the company. JPMorgan Chase & Co. initiated coverage on shares of Septerna in a report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 target price for the company. Wells Fargo & Company began coverage on shares of Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $43.00 price target for the company. Finally, Cantor Fitzgerald began coverage on shares of Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $50.00 price objective on the stock.

Septerna Trading Down 9.0 %

The business has a 50-day moving average price of $23.70.

Insider Activity

In other news, major shareholder Rock Ventures V. L.P. Third bought 370,500 shares of the company’s stock in a transaction dated Monday, October 28th. The shares were bought at an average cost of $18.00 per share, with a total value of $6,669,000.00. Following the acquisition, the insider now owns 6,215,591 shares in the company, valued at $111,880,638. This trade represents a 6.34 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.